▶ 調査レポート

抗うつ剤の世界市場:抗うつ療法別(セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA))、抗うつ障害別(強迫神経症(OCD)、全般性不安障害(GAD)、パニック障害(PD))、治療使用パターン別、地域別分析

• 英文タイトル:Global Antidepressants Market - Segmented by Antidepressants therapies, Depressive Disorders, and Geography - Growth, Trends and Forecasts (2018 - 2023)
• レポートコード:B-MOR-040896
• 出版社/出版日:Mordor Intelligence / 2018年2月
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User(1名様用)¥467,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥495,000 (USD4,500)▷ お問い合わせ
  Corporate User¥962,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、抗うつ剤の世界市場について調べ、抗うつ剤の世界規模、市場動向、市場環境、抗うつ療法別(セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA))分析、抗うつ障害別(強迫神経症(OCD)、全般性不安障害(GAD)、パニック障害(PD))分析、治療使用パターン別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・抗うつ剤の世界市場インサイト
・抗うつ剤の世界市場環境
・抗うつ剤の世界市場動向
・抗うつ剤の世界市場規模
・抗うつ剤の世界市場規模:抗うつ療法別(セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA))
・抗うつ剤の世界市場規模:抗うつ障害別(強迫神経症(OCD)、全般性不安障害(GAD)、パニック障害(PD))
・抗うつ剤の世界市場規模:治療使用パターン別
・抗うつ剤の世界市場:地域別市場規模・分析
・抗うつ剤の北米市場規模・予測
・抗うつ剤のアメリカ市場規模・予測
・抗うつ剤のヨーロッパ市場規模・予測
・抗うつ剤のアジア市場規模・予測
・抗うつ剤の日本市場規模・予測
・抗うつ剤の中国市場規模・予測
・抗うつ剤のインド市場規模・予測
・抗うつ剤の韓国市場規模・予測
・関連企業情報・競争状況

The global antidepressants market has been estimated at USD 11.6 billion in 2017. The market is expected to register a CAGR of 1.8% during the forecast period, 2018 to 2023. North America accounted for the largest market, while Europe is the next to North America in the healthcare asset management market and Asia-Pacific was estimated to register the CAGR growth through the forecast period, 2018-2023.

Number of Patients

Globally, more than 300 million people across all age groups suffer from depression, and this number is rising at a fast pace. The growth in the number of young adults affected by some forms of depression is as high as 8%. Depression due to factors, such as social isolation, stressful work environment, etc. has contributed the most toward increasing the number of people with depression. It is estimated that in a given population about 11% develops one or the other depressive disorder by the age of 18, which becomes a leading cause of suicide. The number of people falling prey to depression and related disorders will continue to increase, as a result of improper eating habits, stressful work schedule, increasing isolation from family and loved ones, due to technology, and the inability to adapt to the rapid pace in which world is moving forward. The depression rate is increasing. So, the market is expected to grow positively in the forecast period due the increase in the number of patients and by increasing the knowledge regarding depression.

Efficacy and Safety Profiles

The major factors restraining the growth of antidepressants market are poor efficacy and safety profiles of drugs, repeated drug failures in many clinical trials, and availability of generics in the market. On the other hand, some meta-analyses (studies that combine the results from many different trials) have shown that antidepressants can certainly be efficacious for some people. According to research publications, it has been found that while antidepressants can be helpful for some, especially among teens with depression, it is the combination of medication and cognitive behavioral therapy that is most effective in achieving remission sooner. So the factors like facilities available in healthcare are restraining the growth of the market along with the other factors such as the issues related to accuracy of these devices and data Integrity and safety is also a limiting the growth of the market.

North America to Dominate the Market Growth

North America accounted for the largest market, accounting for around 36% of the global market share. In North America, due to the presence of a huge patient population suffering from several types of anxiety disorders and depression. Canadians are among the world’s biggest users of antidepressants, with as much as 9% of the population on one depression-fighting drug or another. Like other countries, the use of antidepressants in the US has soared. Along with the North America region, Europe is also the leading region in the global antidepressants market. Asia-Pacific is fastest growing region for antidepressants and portrays huge potential for growth in the future due to increasing prevalence of psychiatric disorders and rapid economic growth in this region.

Key Developments in the Market

• March 2017: Lilly acquired the CoLucid Pharmaceuticals.
• February 2017: Johnson & Johnson acquired the Abbott Medical Optics.

Major Key Players: H. LUNDBECK, ASTRAZENECA, ELI LILLY AND COMPANY, SUN PHARMACEUTICALS, PFIZER INC., GLAXOSMITHKLINE, BRISTOL-MYERS SQUIBB COMPANY, JOHNSON & JOHNSON, MERCK & CO, SANOFI SA

Reasons to Purchase this Report

• Current and future antidepressants market outlook in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis.
• The segment that is expected to dominate the market.
• Regions that are expected to witness fastest growth during the forecast period.
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

レポート目次

1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING NUMBER OF PATIENTS
6.1.2 INCREASE IN AWARENESS LEVEL OF DISEASE STATE
6.1.3 CLINICAL NEEDS POSE A STEADY OPPORTUNITY FOR GROWTH OF EXISTING THERAPIES
6.2 MARKET RESTRAINTS
6.2.1 POOR EFFICACY AND SAFETY PROFILES RESTRAIN USAGE
6.2.2 REPEATED DRUG FAILURES IN CLINICAL TRIALS
6.2.3 AVAILABILITY OF GENERICS AND WEAK PIPELINES
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY ANTIDEPRESSANT THERAPIES
7.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
7.1.2 TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.2 BY DEPRESSIVE DISORDERS
7.2.1 OBSESSIVE-COMPULSIVE DISORDER (OCD)
7.2.2 GENERALIZED ANXIETY DISORDER (GAD)
7.2.3 PANIC DISORDER (PD)
7.3 BY TREATMENTS USING PATTERNS
7.3.1 DISEASED POPULATION
7.3.2 DIAGNOSED POPULATION
7.3.3 PRESCRIPTION POPULATION
7.4 BY GEOGRAPHY
7.4.1 NORTH AMERICA
7.4.1.1 US
7.4.1.2 CANADA
7.4.1.3 MEXICO
7.4.2 EUROPE
7.4.2.1 FRANCE
7.4.2.2 UK
7.4.2.3 GERMANY
7.4.2.4 ITALY
7.4.2.5 SPAIN
7.4.2.6 REST OF EUROPE
7.4.3 ASIA-PACIFIC
7.4.3.1 INDIA
7.4.3.2 CHINA
7.4.3.3 JAPAN
7.4.3.4 AUSTRALIA
7.4.3.5 SOUTH KOREA
7.4.3.6 REST OF APAC
7.4.4 MIDDLE EAST AND AFRICA
7.4.4.1 GCC
7.4.4.2 SOUTH AFRICA
7.4.4.3 REST OF MIDDLE EAST AND AFRICA
7.4.5 SOUTH AMERICA
7.4.5.1 BRAZIL
7.4.5.2 ARGENTINA
7.4.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITIONS
8.2 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS
8.3 NEW PRODUCT LAUNCHES
9. KEY PLAYERS
9.1 H. LUNDBECK
9.2 ASTRAZENECA
9.3 ELI LILLY AND COMPANY
9.4 SUN PHARMACEUTICALS
9.5 PFIZER INC.
9.6 GLAXOSMITHKLINE
9.7 BRISTOL-MYERS SQUIBB COMPANY
9.8 JOHNSON & JOHNSON
9.9 MERCK & CO
9.10 SANOFI S.A
9.11 OTHERS
10. FUTURE OUTLOOK OF THE MARKET




• 英文レポート名:Global Antidepressants Market - Segmented by Antidepressants therapies, Depressive Disorders, and Geography - Growth, Trends and Forecasts (2018 - 2023)
• 日本語訳:抗うつ剤の世界市場:抗うつ療法別(セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA))、抗うつ障害別(強迫神経症(OCD)、全般性不安障害(GAD)、パニック障害(PD))、治療使用パターン別、地域別分析
• レポートコード:B-MOR-040896お問い合わせ(見積依頼・ご注文・質問)